Befotertinib

SI-7835

Befotertinib, >98% (HPLC)

CAS No. : [1835667-63-4]

Synonyms : D-0316

IUPAC Name : N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-(2,2,2-trifluoroethyl)-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide

Price And Availability
Pack Size	Price in USD	Add To Shopping Cart	Availability	Shipping Status
5MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
10MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
25MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
50MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
100MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026

Applications : Befotertinib selectively inhibits mutant EGFR—including T790M, L858R, and delE746‑A750—through covalent engagement of C797, leading to suppression of oncogenic signaling and tumor‑cell proliferation. It also targets ABCB1, blocking drug efflux, activating ATPase activity, and enhancing chemosensitivity and apoptosis in multidrug‑resistant cancer models. This combined EGFR‑ and ABCB1‑directed activity makes Befotertinib valuable for studies of NSCLC and MDR‑associated cancers.

References : Nagasaka M. et al.: J. Thorac. Oncol., 16(5), 740-763, 2021; Blair H. A. Befotertinib: First Approval. Drugs., 83(15), 1433-1437, 2023.

Storage : Keep container tightly closed under nitrogen or argon and refrigerate for long-term shelf life.

Caution : In case of contact with skin or eyes, rinse immediately with plenty of water and seek medical advice. Wear suitable protective clothing and gloves.